About Incyte
Incyte is a company based in Wilmington (United States) founded in 1991. It operates as a Professional Services. The company has 2,620 employees as of December 31, 2024. Incyte has completed 3 acquisitions, including Escient Pharmaceuticals, Proteome and Villaris Therapeutics. Incyte offers products and services including Oncology Solutions and Dermatology Solutions. Incyte operates in a competitive market with competitors including Moderna, BeiGene, MorphoSys, LEO Pharma and Annexon, among others.
- Headquarter Wilmington, United States
- Employees 2620 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Incyte Corporation
-
Annual Revenue
$4.24 B14.76as on Dec 31, 2024
-
Net Profit
$32.62 M-94.54as on Dec 31, 2024
-
EBITDA
$169.39 M-76.94as on Dec 31, 2024
-
Latest Funding Round
$750 M (USD), Post-IPO
Nov 14, 2013
-
Investors
-
Employee Count
2620
as on Dec 31, 2024
-
Investments & Acquisitions
Escient Pharmaceuticals
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Incyte
Incyte is a publicly listed company on the NASDAQ with ticker symbol INCY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Incyte
Incyte offers a comprehensive portfolio of products and services, including Oncology Solutions and Dermatology Solutions. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative treatments for cancer are developed and provided.
Therapies for skin conditions are researched and offered.
Unlock access to complete
Unlock access to complete
Leadership Team
248 people
Software Development Team
124 people
Product Management Team
57 people
Senior Team
48 people
Dermatology Team
45 people
Operations Team
44 people
Legal and Compliance
33 people
Finance and Accounting
28 people
Unlock access to complete
Funding Insights of Incyte
- Total Funding Total Funding
- Total Rounds 1
- Last Round Post-IPO — $750.0M
-
First Round
First Round
(14 Nov 2013)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2013 | Amount | Post-IPO - Incyte | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Incyte
Incyte has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Escient Pharmaceuticals, Proteome and Villaris Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel antibody therapeutics for vitiligo treatment are developed.
|
2019 | ||||
|
Small molecule therapeutics for inflammatory diseases are developed.
|
2017 | ||||
|
Proteomics information is provided to researchers and organizations.
|
1995 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Incyte
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Incyte Comparisons
Competitors of Incyte
Incyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, MorphoSys, LEO Pharma and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating dermatology diseases
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Incyte
Frequently Asked Questions about Incyte
When was Incyte founded?
Incyte was founded in 1991 and raised its 1st funding round 22 years after it was founded.
Where is Incyte located?
Incyte is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Who is the current CEO of Incyte?
Herve Hoppenot is the current CEO of Incyte.
How many employees does Incyte have?
As of Dec 31, 2024, the latest employee count at Incyte is 2,620.
What is the annual revenue of Incyte?
Annual revenue of Incyte is $4.24B as on Dec 31, 2024.
What does Incyte do?
Incyte is engaged in the development of biopharmaceutical solutions targeting unmet medical needs. The company operates in the healthcare sector, with a focus on oncology and dermatology. Innovative treatments and therapies are developed to address complex health challenges. Partnerships and scientific excellence are emphasized to drive patient-centered solutions globally.
Who are the top competitors of Incyte?
Incyte's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
What products or services does Incyte offer?
Incyte offers Oncology Solutions and Dermatology Solutions.
Is Incyte publicly traded?
Yes, Incyte is publicly traded on NASDAQ under the ticker symbol INCY.
How many acquisitions has Incyte made?
Incyte has made 3 acquisitions, including Escient Pharmaceuticals, Proteome, and Villaris Therapeutics.
What is Incyte's ticker symbol?
The ticker symbol of Incyte is INCY on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.